, July 16
/PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for an expanded matrix of sizes for its unique Glider PTCA balloon catheter. Glider is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 3.5mm and in lengths from 4mm to 20mm.
"Glider provides interventional cardiologists with an entirely new degree of control during the treatment of complex side branches and total occlusions," said Dr. David Rizik, Medical Director and Interventional Cardiologist at Scottsdale Heart Group in Scottsdale, AZ. "With its torqueable shaft and ultra short 4mm length, I am amazed that such a clever design can provide such powerful clinical benefits. Glider has become my 'go-to' balloon when I approach the treatment of my most challenging cases."
"Our recent experience in Europe demonstrates Glider's ability to outperform conventional 'best in class' balloon catheters," said Eitan Konstantino, president and CEO of TriReme Medical, Inc. "TriReme now has three product families that have received regulatory approval in the United States. I am proud of our development team that continues to bring to market 'out-of-the-box' solutions to simplify complex interventional procedures."
About Glider: The Glider PTCA Balloon Catheter is the world's only torqueable angioplasty balloon catheter. Combined with its unique balloon shape and state of the art tip technology, the Glider is designed to cross through tight lesions and stent struts even in conditions where other balloons are challenged. The unique design of the Glider provides physicians with a powerful tool in managing the treatment of a broad range of complex lesions such as bifurcations and tight stenoses.
About TriReme Medical, Inc.
Based in Pleasanton, California and Singapore, TriReme Medical, Inc. is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.
SOURCE TriReme Medical, Inc.